Barclays’s Bolt Biotherapeutics BOLT Stock Holding History

Barclays’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23	Hold	6	–	–	﹤0.01%	5281
2026 Q1	$24	Hold	6	–	–	﹤0.01%	4978
2025 Q4	$33	Hold	6	–	–	﹤0.01%	5139
2025 Q3	$32	Hold	6	–	–	﹤0.01%	5334
2025 Q2	$35	Sell	6 -1	-14%	-$7	﹤0.01%	5131
2025 Q1	$56	Hold	7	–	–	﹤0.01%	5144
2024 Q4	$74	Hold	7	–	–	﹤0.01%	5188
2024 Q3	$90	Hold	7	–	–	﹤0.01%	5186
2024 Q2	$104	Hold	7	–	–	﹤0.01%	4755
2024 Q1	$195	Hold	7	–	–	﹤0.01%	4985
2023 Q4	$156	Hold	7	–	–	﹤0.01%	5159
2023 Q3	$145	Hold	7	–	–	﹤0.01%	4537
2023 Q2	$178	Hold	7	–	–	﹤0.01%	4420
2023 Q1	$204	Sell	7 -77	-92%	-$2.25K	﹤0.01%	4976
2022 Q4	$2.18K	Buy	84 +77	+1,100%	+$2.11K	﹤0.01%	5080
2022 Q3	$0	Sell	7 -6	-46%	-$248	﹤0.01%	4802
2022 Q2	$0	Sell	13 -465	-97%	-$18.1K	﹤0.01%	5028
2022 Q1	$26K	Buy	+478	New	+$32.2K	﹤0.01%	4348

Other funds holding BOLT

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T3 Companies New York $93.7M AUM

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's BOLT Position: Q2 2026 in Review

Barclays held its Bolt Biotherapeutics (BOLT) position steady in Q2 2026 at 6 shares worth $23. The position accounts for ﹤0.01% of the portfolio, ranked #5281.

Barclays first reported a position in BOLT in Q1 2022 and has held it in 18 quarters since. The position peaked at $26K in Q1 2022. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

Barclays held 6 shares of Bolt Biotherapeutics worth $23 as of Q2 2026.
Barclays left its Bolt Biotherapeutics share count unchanged in Q2 2026.
Bolt Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5281 holding.
Barclays first reported a position in Bolt Biotherapeutics in Q1 2022 and has held it in 18 quarters since.
Barclays's Bolt Biotherapeutics position peaked at $26K in Q1 2022.
23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.